Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci

Surgical Infections

Volumn 6, Issue SUPPL. 2, 2005, Pages

  Napolitano, Lena M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; IMIPENEM; LINCOSAMIDE; LINEZOLID; LUNG SURFACTANT; MACROLIDE; METICILLIN; MIKAMYCIN B; ORITAVANCIN; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANBEZOLID; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTHRALGIA; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; DIABETIC FOOT; DIAGNOSTIC TEST; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INACTIVATION; DRUG MECHANISM; DRUG PENETRATION; DRUG PREFERENCE; EDEMA; EPIDEMIOLOGICAL DATA; GRAM POSITIVE COCCI; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; INJECTION SITE REACTION; LEUKOPENIA; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MULTIDRUG RESISTANCE; MUSCLE DISEASE; MYALGIA; NAUSEA AND VOMITING; PAIN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; THROMBOCYTOPENIA; THROMBOPHLEBITIS; UNITED STATES; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA; WOUND INFECTION;

EID: 26444530015     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2005.6.s2-5     Document Type: Review

References (80)

1. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7:178-188.
2. Jones RN, Low DE, Pfaller MA. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: The role of streptogramins and other newer compounds. Diagn Microbiol Infect Dis 1999;33:101-112.
3. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003;36: 53-59.
4. Taylor MD, Napolitano LM. Methicillin-resistant Staphylococcus aureus infections in vascular surgery: Increasing prevalence. Surg Infect 2004;5:180-187.
5. Zinn CS, Westh H, Rosdahl VT; Sarisa Study Group. An international multicenter study of antimicrobial resistance and typing of hospital Staphylococcus aureus isolates from 21 laboratories in 19 countries or states. Microb Drug Resist 2004;10:160-168.
6. National Nosocomial Infections Surveillance (NNIS) System Report, data summary, from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-485.
7. Francois P, Pittet D, Bento M, et al. Rapid detection of methicillin-resistant Staphylococcus aureus directly from sterile or nonsterile clinical samples by a new molecular assay. J Clin Microbiol 2003;4:254-260.
8. Huletsky A, Giroux R, Rossbach V, et al. New real-time PCR assay for rapid detection of methicillin-resistant Staphylococcus aureus directly from specimens containing a mixture of staphylococci. J Clin Microbiol 2004;42:1875-1884.
9. Warren DK, Liao RS, Merz LR, et al. Detection of methicillin-resistant Staphylococcus aureus directly from nasal swab specimens by a real-time PCR assay. J Clin Microbiol 2004;42:5578-5581.
10. Nagasawa Z, Manome I, Nagayama A. A rapid antimicrobial susceptibility test based on chemiluminescence assay and its application to screening of genotypes in vancomycin-resistant enterococci. J Infect Chemother 2004;10:220-226.
11. Clark NC, Weigel LM, Patel JB, et al. Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania. Antimicrob Agents Chemother 2005;49:470-472.
12. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999;340:493-501.
13. Bozdogan B, Ednie L, Credito K, et al. Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicrob Agents Chemother 2004;48:4762-4765.
14. Hussain FM, Boyle-Vavra S, Shete PB, et al. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J Infect Dis 2002;186:661-667.
15. Rybak MJ, Cha R, Cheung CM, et al. Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. Diagn Microbiol Infect Dis 2005;51:119-125.
16. Fridkin SK, Hageman J, McDougal LK, et al, Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003;36:429-439.
17. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-2984.
18. Holden MT, Feil EJ, Lindsay JA, Peacock SJ, et al. Complete genomes of two clinical Staphylococcus aureus strains: Evidence for the rapid evolution of virulence and drug resistance. Proc Natl Acad Sci U S A 2004;10:9786-9791.
19. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005;352: 468-475.
20. Carleton HA, Diep BA, Charlebois ED, Sensabaugh GF, Perdreau-Remington F. Community-adapted methicillin-resistant Staphylococcus aureus (MRSA): population dynamics of an expanding community reservoir of MRSA. J Infect Dis. 2004;190:1730-1738. Epub 2004 Oct 18.
21. Johnsson D, Molling P, Stralin K, Soderquist B. Detection of Panton-Valentine leukocidin gene in Staphylococcus aureus by LightCycler PCR: clinical and epidemiological aspects. Clin Microbiol Infect. 2004;10: 884-889.
22. Lewis JS 2nd, Jorgensen JH. Inducible clindamycin resistance in Staphylococci: Should clinicians and microbiologists be concerned? Clin Infect Dis 2005;40: 280-285.
23. Siberry GK, Tekle T, Carroll K, et al. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003;37:1257-1260.
24. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-474.
25. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742-2751.
26. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft-tissue infections caused by known or suspected methicillin-resistant staphylococci: Results from a randomized clinical trial. Surg Infect 2003;4:57-70.
27. Carpenter CF, Chambers HF. Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38:994-1000.
28. Anstead GM, Owens AD. Recent advances in the treatment of infections due to resistant Staphylococcus aureus. Curr Opin Infect Dis 2004;17:549-555.
29. Fritsche TR, Jones RN. Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int J Antimicrob Agents 2004;24:567-571.
30. Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004;49:201-209.
31. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220-229.
32. Napolitano LM. Hospital-acquired and ventilator-associated pneumonia: What's new in diagnosis and treatment? Am J Surg 2003;186: 4S-14S.
33. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus: Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994;150:1545-1549.
34. Fagon J, Patrick H, Haas DW, et al. for the Nosocomial Pneumonia Group. Treatment of gram-positive nosocomial pneumonia: Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000;161:753-762.
35. Rubinstein E, Cammarata SK, Oliphant TH, et al. Linezolid versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-412.
36. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs. vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124: 1789-1797.
37. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in gram-positive ventilator-associated pneumonia: Retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388-394.
38. Conte JE Jr, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475-1480.
39. Honeybourne D, Tobin C, Jevons G, et al. Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003;51:1431-1434.
40. Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993;37:281-286.
41. Georges H, Leroy O, Alfandari S, et al. Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis 1997;16:385-388.
42. Nasraway SA, Shorr AF, Kuter DJ, et al. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: Comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003;37:1609-1616.
43. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191:2149-2152.
44. Wilson MA. Skin and soft-tissue infections: Impact of resistant gram-positive bacteria. Am J Surg 2003;186: 35S-41S; discussion 42S-43S, 61S-64S.
45. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA. Expert panel on managing skin and soft tissue infections. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52(Suppl 1):i3-17.
46. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999;44:263-273.
47. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-1490.
48. Weigelt J, Itani KM, Lau WK, et al. Linezolid vs. vancomycin for complicated skin and skin structure infections presumed or known to be caused by methicillin-resistant S. aureus. San Diego, California. Infectious Disease Society of America Annual Meeting 2003: Poster #314.
49. Weigelt J, Kaafarani HM, Itani KM, et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004;188:760-766.
50. Stein GE, Schooley SL, Peloquin CA, et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005 Feb 8; [Epub ahead of print].
51. Anonymous. Daptomycin (Cubicin) for skin and soft-tissue infections. Med Lett Drugs Ther 2004;46:11-12.
52. Steenbergen JN, Alder J, Thorne GM, et al. Daptomycin: A lipopeptide antibiotic for the treatment of serious gram-positive infections. J Antimicrob Chemother 2005 Feb 10; [Epub ahead of print].
53. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI; Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673-81. Epub 2004 May 20
54. Raghavan M, Linden PK. Newer treatment options for skin and soft-tissue infections. Drugs 2004;64: 1621-1642.
55. Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003;37:1298-1303.
56. Lin G, Credito K, Ednie LM, et al. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005;49:770-772.
57. Loutit JS, Huang SM, Porter SB. Efficacy and safety of oritavancin in the treatment of diabetic patients with complicated skin and skin structure infections. Int J Infect Dis 2004;8(Suppl 1):S18 (Abstract).
58. Ellis-Grosse EJ, Loh E. Tigecycline is safe and effective in the treatment of skin and skin structure infections: results of two double-blind phase 3 comparison studies with vancomycin/aztreonam (abstract FP-C-6). Presented at the 9th Western Pacific Congress on Chemotherapy and Infectious Diseases, December 1-5, 2004, Bangkok, Thailand.
59. Lipsky BA, Itani K, Norden C, and the Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: A randomized, multicenter, open-label trial of linezolid vs. ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004;38:17-24.
60. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: Evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005;55:240-245.
61. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999;29: 234-244.
62. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003;36: 53-59.
63. Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 2001;175:264-267.
64. Lodise TP, McKinnon PS, Swiderski L, et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003;36:1418-1423.
65. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003;36:429-439.
66. Charles PG, Ward PB, Johnson PDR, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004;38:448-451.
67. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-2402.
68. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005;40:374-380.
69. Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs. 2002;62:425-441.
70. Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enteracoccus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999;44: 251-261.
71. El-Khoury J, Fishman JA. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: Report of a multicenter compassionate-use trial. Transpl Infect Dis 2003;5:121-125.
72. Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004;53:646-649.
73. Cercenado E, Cercenado S, Gomez JA, Bouza E. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 2003;52: 138-139.
74. Guay DR. Oritavancin and tigecycline: Investigational antimicrobials for multi-drug-resistant bacteria. Pharmacotherapy 2004;24:58-68.
75. Tsuji M, Takema M, Miwa H, et al. In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: Methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models. Antimicrob Agents Chemother 2003;47: 2507-2512.
76. Vouillamoz J, Entenza JM, Hohl P, et al. LB11058, a new cephalosporin with high penicillin-binding protein 2a affinity and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004;48:4322-4327.
77. Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 2004;48:3043-3050.
78. Ueda Y, Sunagawa M. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1-beta-methylcarbapenems with potent activities against multi-resistant gram-positive bacteria. Antimicrob Agents Chemother 2003;47:2471-2480.
79. Kurazono M, Ida T, Yamada K, et al. In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2004;48:2831-2837.
80. Mathur T, Bhateja P, Pandya M, et al. In vitro activity of RBx 7644 (ranbezolid) on biofilm producing bacteria. Int J Antimicrob Agents 2004;24:369-373.